E. Goncalves

The pharmacoepigenomic landscape of cancer cell lines reveals the epigenetic component of drug sensitivity

The paper identifies DNA methylation biomarkers linked to drug sensitivity in cancer cell lines across multiple cancer types and drugs.

Base editing screens map mutations affecting IFNγ signalling in cancer

This study uses base editing to identify mutations affecting IFNγ signalling in cancer, revealing loss- and gain-of-function variants with clinical relevance.

A suspension technique for efficient large-scale cancer organoid culturing and perturbation screens

This paper introduces a suspension culture technique for cancer organoids that improves expansion efficiency and enables large-scale perturbation screens.

Evidence of post-domestication hybridization and adaptive introgression in Western European grapevine varieties

This study uses whole genome resequencing to show post-domestication hybridization and adaptive introgression in Western European grapevine varieties, with strong signals in Iberian varieties.

Agreement between two large pan-cancer CRISPR-Cas9 gene dependency datasets

This study compares two large pan-cancer CRISPR-Cas9 screens, finding high concordance in gene dependencies despite differences in protocols and reagents.

Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR/Cas9 screening

The paper functionally links gene fusions to cancer cell fitness using drug sensitivity and CRISPR-Cas9 data, identifying rare functional fusions and novel therapeutic targets.

Forest canopy, a proxi of light intensity, arrests Pinus radiata invasion: basic science to conserve the Coastal Maulino forest, Central Chile.

The study finds that canopy cover reduces Pinus radiata seedling density in Coastal Maulino forest fragments, suggesting canopy preservation is key to conserving native biodiversity.

Prioritisation of oncology therapeutic targets using CRISPR-Cas9 screening

This study uses CRISPR-Cas9 screens in cancer cell lines to identify and prioritize new oncology therapeutic targets based on gene fitness, biomarkers, and tractability.